Michaela Bennett scite author profile

Recent phase 2b and phase 3 clinical trials support the safety and efficacy of the selective Janus kinase (JAK)‐1 inhibitor upadacitinib (UPA) in the treatment of moderate to severe atopic dermatitis (AD). However, to date, there is little experience with UPA therapy for AD in Australia. We report findings from a retrospective study to better understand the therapeutic response and side effects noted in a single‐centre Australian cohort.

show abstract

Unmet needs for community-based physiotherapy services for adults in Canada and the United States: a scoping review protocol

Hock¹,

Beley²,

Bennett³

et al. 2020

Phys Med Rehabil Res

View full text Add to dashboard Cite

Clear Cell Acanthoma: Sural Nerve Entrapment and Neuropathy After Excision

Bennett

Sinclair

2021

Dermatol Surg

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.